Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.
PAION AG reports on fiscal year 2019
PAION AG: Cosmo announces brief extension of FDA review period for NDA for remimazolam
Cosmo sub-licenses its ByFavo™ (Remimazolam) US rights to Acacia Pharma, takes an initial 14.1% stake and provides finance for Acacia Pharma’s US expansion
PAION grants remimazolam license for Southeast Asia to Hana Pharm